Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ANIP vs AMRX vs LNTH vs PRGO vs PAHC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ANIP
ANI Pharmaceuticals, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$1.78B
5Y Perf.+170.2%
AMRX
Amneal Pharmaceuticals, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$4.31B
5Y Perf.+181.7%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5.92B
5Y Perf.+562.8%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-78.6%
PAHC
Phibro Animal Health Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$1.75B
5Y Perf.+64.7%

ANIP vs AMRX vs LNTH vs PRGO vs PAHC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ANIP logoANIP
AMRX logoAMRX
LNTH logoLNTH
PRGO logoPRGO
PAHC logoPAHC
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$1.78B$4.31B$5.92B$1.61B$1.75B
Revenue (TTM)$883M$3.02B$1.55B$4.18B$1.46B
Net Income (TTM)$78M$72M$279M$-1.82B$92M
Gross Margin69.1%36.9%60.5%34.2%31.9%
Operating Margin12.6%-0.2%18.8%-4.1%11.6%
Forward P/E9.2x13.8x17.5x5.6x14.2x
Total Debt$325M$124M$738K$3.97B$762M
Cash & Equiv.$286M$282M$359M$532M$68M

ANIP vs AMRX vs LNTH vs PRGO vs PAHCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ANIP
AMRX
LNTH
PRGO
PAHC
StockMay 20May 26Return
ANI Pharmaceuticals… (ANIP)100270.2+170.2%
Amneal Pharmaceutic… (AMRX)100281.7+181.7%
Lantheus Holdings, … (LNTH)100662.8+562.8%
Perrigo Company plc (PRGO)10021.4-78.6%
Phibro Animal Healt… (PAHC)100164.7+64.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: ANIP vs AMRX vs LNTH vs PRGO vs PAHC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LNTH leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. ANIP and PAHC also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ANIP
ANI Pharmaceuticals, Inc.
The Growth Play

ANIP ranks third and is worth considering specifically for growth exposure.

  • Rev growth 43.8%, EPS growth 419.2%, 3Y rev CAGR 40.8%
  • 43.8% revenue growth vs PRGO's -2.8%
Best for: growth exposure
AMRX
Amneal Pharmaceuticals, Inc.
The Value Angle

Among these 5 stocks, AMRX doesn't own a clear edge in any measured category.

Best for: healthcare exposure
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 41.9% 10Y total return vs PAHC's 128.6%
  • Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
  • 18.0% margin vs PRGO's -43.5%
  • Beta 0.47 vs PAHC's 1.38, lower leverage
Best for: long-term compounding and sleep-well-at-night
PRGO
Perrigo Company plc
The Income Pick

PRGO is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.

  • Dividend streak 10 yrs, beta 1.18, yield 9.8%
  • Beta 1.18, yield 9.8%, current ratio 2.76x
  • Lower P/E (5.6x vs 14.2x)
  • 9.8% yield, 10-year raise streak, vs ANIP's 0.1%, (2 stocks pay no dividend)
Best for: income & stability and defensive
PAHC
Phibro Animal Health Corporation
The Momentum Pick

PAHC is the clearest fit if your priority is momentum.

  • +125.1% vs PRGO's -51.2%
Best for: momentum
See the full category breakdown
CategoryWinnerWhy
GrowthANIP logoANIP43.8% revenue growth vs PRGO's -2.8%
ValuePRGO logoPRGOLower P/E (5.6x vs 14.2x)
Quality / MarginsLNTH logoLNTH18.0% margin vs PRGO's -43.5%
Stability / SafetyLNTH logoLNTHBeta 0.47 vs PAHC's 1.38, lower leverage
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs ANIP's 0.1%, (2 stocks pay no dividend)
Momentum (1Y)PAHC logoPAHC+125.1% vs PRGO's -51.2%
Efficiency (ROA)LNTH logoLNTH12.4% ROA vs PRGO's -19.8%, ROIC 30.6% vs 3.7%

ANIP vs AMRX vs LNTH vs PRGO vs PAHC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ANIPANI Pharmaceuticals, Inc.
FY 2024
Total Sales of Generics and Other
52.1%$320M
Sales of rare disease pharmaceutical products
37.4%$230M
Sales of Established Brands
10.5%$65M
AMRXAmneal Pharmaceuticals, Inc.
FY 2024
Specialty Segment
100.0%$446M
LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
PAHCPhibro Animal Health Corporation
FY 2025
Vaccines
100.0%$137M

ANIP vs AMRX vs LNTH vs PRGO vs PAHC — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLNTHLAGGINGPAHC

Income & Cash Flow (Last 12 Months)

LNTH leads this category, winning 3 of 6 comparable metrics.

PRGO is the larger business by revenue, generating $4.2B annually — 4.7x ANIP's $883M. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ANIP holds the edge at +29.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricANIP logoANIPANI Pharmaceutica…AMRX logoAMRXAmneal Pharmaceut…LNTH logoLNTHLantheus Holdings…PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
RevenueTrailing 12 months$883M$3.0B$1.5B$4.2B$1.5B
EBITDAEarnings before interest/tax$203M$169M$347M$58M$220M
Net IncomeAfter-tax profit$78M$72M$279M-$1.8B$92M
Free Cash FlowCash after capex$128M$150M$372M$108M$47M
Gross MarginGross profit ÷ Revenue+69.1%+36.9%+60.5%+34.2%+31.9%
Operating MarginEBIT ÷ Revenue+12.6%-0.2%+18.8%-4.1%+11.6%
Net MarginNet income ÷ Revenue+8.9%+2.4%+18.0%-43.5%+6.3%
FCF MarginFCF ÷ Revenue+14.5%+5.0%+24.0%+2.6%+3.2%
Rev. Growth (YoY)Latest quarter vs prior year+29.6%+11.5%+1.2%-7.2%+20.9%
EPS Growth (YoY)Latest quarter vs prior year+3.1%+2.1%+76.5%-56.4%+7.4%
LNTH leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 5 of 6 comparable metrics.

At 25.3x trailing earnings, ANIP trades at a 59% valuation discount to AMRX's 62.4x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than PAHC's 15.7x.

MetricANIP logoANIPANI Pharmaceutica…AMRX logoAMRXAmneal Pharmaceut…LNTH logoLNTHLantheus Holdings…PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
Market CapShares × price$1.8B$4.3B$5.9B$1.6B$1.7B
Enterprise ValueMkt cap + debt − cash$1.8B$4.2B$5.6B$5.1B$2.4B
Trailing P/EPrice ÷ TTM EPS25.27x62.36x26.69x-1.14x36.27x
Forward P/EPrice ÷ next-FY EPS est.9.25x13.81x17.52x5.56x14.23x
PEG RatioP/E ÷ EPS growth rate4.85x
EV / EBITDAEnterprise value multiple8.99x14.61x7.42x15.65x
Price / SalesMarket cap ÷ Revenue2.02x1.43x3.84x0.38x1.35x
Price / BookPrice ÷ Book value/share3.29x4.62x5.72x0.55x6.15x
Price / FCFMarket cap ÷ FCF9.62x15.98x16.73x11.12x41.82x
PRGO leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

LNTH leads this category, winning 7 of 9 comparable metrics.

PAHC delivers a 30.8% return on equity — every $100 of shareholder capital generates $31 in annual profit, vs $-51 for PRGO. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to PAHC's 2.67x. On the Piotroski fundamental quality scale (0–9), AMRX scores 8/9 vs PRGO's 4/9, reflecting strong financial health.

MetricANIP logoANIPANI Pharmaceutica…AMRX logoAMRXAmneal Pharmaceut…LNTH logoLNTHLantheus Holdings…PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
ROE (TTM)Return on equity+14.5%+7.5%+24.3%-50.7%+30.8%
ROA (TTM)Return on assets+5.4%+2.0%+12.4%-19.8%+6.7%
ROICReturn on invested capital+11.2%-0.2%+30.6%+3.7%+9.8%
ROCEReturn on capital employed+9.9%-0.2%+17.1%+4.3%+12.0%
Piotroski ScoreFundamental quality 0–968545
Debt / EquityFinancial leverage0.60x0.13x0.00x1.35x2.67x
Net DebtTotal debt minus cash$40M-$158M-$358M$3.4B$694M
Cash & Equiv.Liquid assets$286M$282M$359M$532M$68M
Total DebtShort + long-term debt$325M$124M$738,000$4.0B$762M
Interest CoverageEBIT ÷ Interest expense1.82x2.09x11.72x-7.20x3.64x
LNTH leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LNTH leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $3,986 for PRGO. Over the past 12 months, PAHC leads with a +125.1% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors AMRX at 89.4% vs PRGO's -25.2% — a key indicator of consistent wealth creation.

MetricANIP logoANIPANI Pharmaceutica…AMRX logoAMRXAmneal Pharmaceut…LNTH logoLNTHLantheus Holdings…PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
YTD ReturnYear-to-date+7.0%+8.4%+35.3%-13.5%+16.0%
1-Year ReturnPast 12 months+18.5%+90.0%+13.1%-51.2%+125.1%
3-Year ReturnCumulative with dividends+97.1%+579.2%-4.0%-58.1%+210.4%
5-Year ReturnCumulative with dividends+117.4%+163.8%+314.2%-60.1%+66.0%
10-Year ReturnCumulative with dividends+84.7%-54.9%+4192.5%-77.7%+128.6%
CAGR (3Y)Annualised 3-year return+25.4%+89.4%-1.4%-25.2%+45.9%
LNTH leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

LNTH leads this category, winning 2 of 2 comparable metrics.

LNTH is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than PAHC's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricANIP logoANIPANI Pharmaceutica…AMRX logoAMRXAmneal Pharmaceut…LNTH logoLNTHLantheus Holdings…PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
Beta (5Y)Sensitivity to S&P 5000.63x1.17x0.47x1.18x1.38x
52-Week HighHighest price in past year$99.50$15.20$93.00$28.44$60.08
52-Week LowLowest price in past year$56.71$7.02$47.25$9.23$19.00
% of 52W HighCurrent price vs 52-week peak+84.3%+90.3%+97.8%+41.2%+71.8%
RSI (14)Momentum oscillator 0–10064.462.761.260.960.3
Avg Volume (50D)Average daily shares traded328K1.7M886K3.4M302K
LNTH leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

PRGO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: ANIP as "Buy", AMRX as "Buy", LNTH as "Buy", PRGO as "Hold", PAHC as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 11.0% for LNTH (target: $101). For income investors, PRGO offers the higher dividend yield at 9.81% vs PAHC's 1.11%.

MetricANIP logoANIPANI Pharmaceutica…AMRX logoAMRXAmneal Pharmaceut…LNTH logoLNTHLantheus Holdings…PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHoldBuy
Price TargetConsensus 12-month target$124.00$17.00$101.00$20.00$49.00
# AnalystsCovering analysts1016173613
Dividend YieldAnnual dividend ÷ price+0.1%+9.8%+1.1%
Dividend StreakConsecutive years of raises000100
Dividend / ShareAnnual DPS$0.05$1.15$0.48
Buyback YieldShare repurchases ÷ mkt cap+0.7%0.0%+5.1%0.0%0.0%
PRGO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

LNTH leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook).

Best OverallLantheus Holdings, Inc. (LNTH)Leads 4 of 6 categories
Loading custom metrics...

ANIP vs AMRX vs LNTH vs PRGO vs PAHC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ANIP or AMRX or LNTH or PRGO or PAHC a better buy right now?

For growth investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger pick with 43. 8% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). ANI Pharmaceuticals, Inc. (ANIP) offers the better valuation at 25. 3x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate ANI Pharmaceuticals, Inc. (ANIP) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ANIP or AMRX or LNTH or PRGO or PAHC?

On trailing P/E, ANI Pharmaceuticals, Inc.

(ANIP) is the cheapest at 25. 3x versus Amneal Pharmaceuticals, Inc. at 62. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — ANIP or AMRX or LNTH or PRGO or PAHC?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ANIP or AMRX or LNTH or PRGO or PAHC?

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 194% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — ANIP or AMRX or LNTH or PRGO or PAHC?

By revenue growth (latest reported year), ANI Pharmaceuticals, Inc.

(ANIP) is pulling ahead at 43. 8% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ANIP or AMRX or LNTH or PRGO or PAHC?

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — ANIP leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ANIP or AMRX or LNTH or PRGO or PAHC more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 17. 5x for Lantheus Holdings, Inc. — 12. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

08

Which pays a better dividend — ANIP or AMRX or LNTH or PRGO or PAHC?

In this comparison, PRGO (9.

8% yield), PAHC (1. 1% yield) pay a dividend. ANIP, AMRX, LNTH do not pay a meaningful dividend and should not be held primarily for income.

09

Is ANIP or AMRX or LNTH or PRGO or PAHC better for a retirement portfolio?

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (LNTH: +41. 9%, AMRX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ANIP and AMRX and LNTH and PRGO and PAHC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ANIP is a small-cap high-growth stock; AMRX is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; PAHC is a small-cap high-growth stock. PRGO, PAHC pay a dividend while ANIP, AMRX, LNTH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ANIP

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

AMRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 22%
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

PAHC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ANIP and AMRX and LNTH and PRGO and PAHC on the metrics below

Revenue Growth>
%
(ANIP: 29.6% · AMRX: 11.5%)
Net Margin>
%
(ANIP: 8.9% · AMRX: 2.4%)
P/E Ratio<
x
(ANIP: 25.3x · AMRX: 62.4x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.